This study is to investigate the effect and its possible mechanisms of lidamycin (LDM) combined with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in human non-small cell lung cancer (NSCLC) cells.
研究力达霉素(LDM)与肿瘤坏死因子相关的凋亡诱导配体(TRAIL)联合作用对非小细胞肺癌细胞株H460细胞的增效作用及其作用机制。
参考来源 - 力达霉素联合TRAIL对非小细胞肺癌的协同作用及其机制·2,447,543篇论文数据,部分数据来源于NoteExpress
应用推荐